Novartis flagged a first annual profit drop in years for 2026 as key patents expire on blockbuster therapies including Entresto and Xolair, warning that generic competition could drive roughly $4 billion in negative earnings impact. The company’s disclosure ties the expected earnings headwinds to the timing of patent expirations and the likely entry of lower-cost competitors. That projection is especially relevant for planning portfolio reallocation and pipeline acceleration as branded revenues come under pressure. For the industry, the update is a reminder that late-cycle commercial assumptions increasingly hinge on patent calendars, launch readiness for successors, and payer conversion dynamics in major markets. With major product classes approaching patent cliffs across big pharma, the market’s attention will likely shift to whether growth engines—late-stage assets and new indications—can offset the decline.